Total
0
Shares
Revasum (ASX:RVS) raises almost $7M via institutional entitlement offer
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors
  • The agreements with Deakin University’s Institute for Frontier Materials (DIFM) and Swinburne university of Technology will progress the commercialisation of the Tn Antigen biosensor and the development of other biosensors using UBI’s electrochemical platform technology
  • UBI has contracted Dr Wren Green and Dr Saimon Moraes Silva to work on the project, with fees falling collectively under $300,000 per annum
  • Universal Biosensors shares are up 9.68 per cent, trading at 68 cents

Universal Biosensors (UBI) has entered into exclusive agreements for the development of its biosensors.

The agreements with Deakin University’s Institute for Frontier Materials (DIFM) and Swinburne University of Technology will progress the commercialisation of the Tn Antigen biosensor, used for the detection, staging and monitoring of cancer, as well as the development of other biosensors using UBI’s electrochemical platform technology.

The Deakin University agreement contracts 50 per cent of the of Senior Fellow Dr Wren Green’s time and resources to UBI. The agreement is for a five-year term, for a fixed fee.

The Swinburne agreement contracts 80 per cent of Dr Saimon Moraes Silva’s time, also under a fixed fee, ending in February 2022. Dr Saimon will work under the supervision of Professor Simon Moulton of Swinburne’s School Software and Electrical Engineering and Iverson Health Innovation Research Institute.

Both agreements have fees payable by UBI, collectively coming under $300,000 per year.

“Using UBI’s platform technology we plan to deliver a cancer biosensor capable of identifying, staging and monitoring cancer from a finger prick of blood, using a portable hand held device,” said CEO of UBI John Sharman.

“The knowledge and resources of DIFM and Swinburne will help deliver this as well as fast track the development of other biosensors we are working on.”

Universal Biosensors shares are up 9.68 per cent, trading at 68 cents at 1:15 pm AEST.

UBI by the numbers
More From The Market Herald
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract

AnteoTech (ADO) has finalised and signed a contract manufacturing agreement with Spanish manufacturer, Operon.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito - The Market Herald

" Botanix Pharmaceuticals (ASX:BOT) receives encouraging results from canine study

Botanix Pharmaceuticals (BOT) says it has received encouraging results from a small pilot study of its synthetic CBD treatment in canines with atopic
Healthia (ASX:HLA) to purchase The Eyecare Place

" Healthia (ASX:HLA) to purchase The Eyecare Place

Healthia (HLA) has entered into agreements to purchase The Eyecare Place, an optical store located in Abbotsford, Victoria.
Avita Therapeutics (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald

" Avita Medical (ASX:AVH) reports solid revenue growth over March quarter

Avita Medical (AVH) reported a 126-per-cent revenue increase and steady growth in procedural volumes in its review of the March quarter.